These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23883268)

  • 1. Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion.
    Kim BT; Schwartz SG; Smiddy WE; Doshi RR; Kovach JL; Berrocal AM; Moshfeghi AA; Fortun JA
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(4):334-43. PubMed ID: 23883268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
    Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK
    Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
    Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
    Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
    Varma R; Haller JA; Kaiser PK
    JAMA Ophthalmol; 2015 Sep; 133(9):997-1004. PubMed ID: 26068086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin.
    Warrow DJ; Lai MM; Patel A; Raevis J; Berinstein DM
    Am J Ophthalmol; 2015 Jan; 159(1):20-30.e1. PubMed ID: 25220823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
    Jackson TL; Regillo CD; Girach A; Dugel PU;
    Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration.
    Novack RL; Staurenghi G; Girach A; Narendran N; Tolentino M
    Ophthalmology; 2015 Apr; 122(4):796-802. PubMed ID: 25435217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology of Internal Limiting Membrane Specimens Following Intravitreal Injection of Ocriplasmin.
    Schumann RG; Wolf A; Mayer WJ; Compera D; Hagenau F; Ziada J; Kampik A; Haritoglou C
    Am J Ophthalmol; 2015 Oct; 160(4):767-78. PubMed ID: 26133247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.
    Haller JA; Stalmans P; Benz MS; Gandorfer A; Pakola SJ; Girach A; Kampik A; Jaffe GJ; Toth CA;
    Ophthalmology; 2015 Jan; 122(1):117-22. PubMed ID: 25240630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin].
    Lommatzsch AP; Gutfleisch M; Dietzel M; Heimes B; Spital G; Böhme M; Bornfeld N; Pauleikhoff D
    Klin Monbl Augenheilkd; 2014 Sep; 231(9):909-14. PubMed ID: 24788606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ocriplasmin on the management of macular holes: assessment of the clinical relevance of ocriplasmin.
    Moisseiev J; Moroz I; Katz G
    JAMA Ophthalmol; 2014 Jun; 132(6):709-13. PubMed ID: 24723009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RESOLUTION OF SUBRETINAL FLUID AND OUTER RETINAL CHANGES IN PATIENTS TREATED WITH OCRIPLASMIN.
    Nudleman E; Franklin MS; Wolfe JD; Williams GA; Ruby AJ
    Retina; 2016 Apr; 36(4):738-43. PubMed ID: 26398688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion.
    Meyer JC; Shah GK; Blinder KJ; Waheed NK; Reichel E; Stalmans P; Singer M; Tewari A
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):209-16. PubMed ID: 25707046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
    Modi YS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
    Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
    Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
    Lenk J; Matthé E; Ventzke S; Pillunat LE; Sandner D
    Klin Monbl Augenheilkd; 2018 Jan; 235(1):73-80. PubMed ID: 28282697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.